Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 20/20 | 0.65 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839474 | 1.00 | MALT1 (0.65) | MALT1BIRC3 | |
| SCHEMBL18839594 | 0.90 | MALT1 (0.73) | MALT1BIRC3 | |
| SCHEMBL18839592 | 0.90 | MALT1 (0.73) | MALT1BIRC3 | |
| SCHEMBL18839583 | 0.88 | MALT1 (0.64) | MALT1BIRC3 | |
| SCHEMBL18839867 | 0.88 | MALT1 (0.83) | MALT1BIRC3 | |
| SCHEMBL18839870 | 0.88 | MALT1 (0.83) | MALT1BIRC3 | |
| SCHEMBL18839581 | 0.88 | MALT1 (0.64) | MALT1BIRC3 | |
| SCHEMBL18839567 | 0.86 | MALT1 (0.62) | MALT1BIRC3 | |
| SCHEMBL18839563 | 0.86 | MALT1 (0.62) | MALT1BIRC3 | |
| SCHEMBL18839578 | 0.84 | MALT1 (0.66) | MALT1BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | claimed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | claimed |
| WO-2018141749-A1 | THERAPEUTIC APPLICATIONS OF MALT1 INHIBITORS | MEDIVIR AB (SE) | 2018-08-09 | — | — | WO | claimed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | claimed |
| EP-3731848-B1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | MASSACHUSETTS GEN HOSPITAL (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4243812-A1 | MATERIALS AND METHODS OF TREATING CANCER | Monopteros Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-27 | — | — | US | disclosed |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022101676-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS,INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021262969-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3731848-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | The General Hospital Corporation (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| WO-2018141749-A1 | THERAPEUTIC APPLICATIONS OF MALT1 INHIBITORS | MEDIVIR AB (SE) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | CD47, ICOS, LCK | MALT1 133/4885BIRC3 351/4885 |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, CD274, TP53 | MALT1 1/4885BIRC3 120/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | MALT1 4/4885BIRC3 49/4885 |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | CD47, ICOS, LCK | MALT1 133/4885BIRC3 351/4885 |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, TP53, RAD1 | MALT1 1/4885BIRC3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.